$Cassava Sciences (SAVA.US)$ This Open Letter is definitely ...
$Cassava Sciences (SAVA.US)$ This Open Letter is definitely showing that SAVA is about treating patients with AD and debunks all the crap the shorts have done for 3+ years. ’I am happy to inform you that our ReTHINK Phase 3 clinical trial recently completed its last patient, last visit. All patients have completed dosing, and all that remains is to collect and analyze the data. For a company our size, this is a remarkable achievement. This study enrolled 804 patients at 77 sites in the US, Puerto Rico, Canada, and Australia. Patients were randomized 1:1 between placebo and simufilam 100 mg, twice daily. Approximately 70% of the patients entered the study with mild Alzheimer's disease, while 30% entered with moderate Alzheimer's.
We expect to announce top-line results of the ReTHINK trial before year end’
We expect to announce top-line results of the ReTHINK trial before year end’
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
